URGN - UroGen Pharma Ltd.

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• UroGen files to sell 12.6M shares of common stock for holders
• UroGen Pharma GAAP EPS of -$1.03 beats by $0.10, revenue of $21.14M beats by $1.02M
• UroGen says bladder cancer therapy met main goals in Phase 3 trials
• UroGen Pharma GAAP EPS of -$1.30 beats by $0.01, revenue of $17.19M beats by $0.1M
• UroGen Pharma jumps amid takeover speculation
• UroGen Pharma GAAP EPS of -$1.22 misses by $0.14, revenue of $18.09M misses by $0.42M
• UroGen Pharma falls after Jefferies lower rating to hold
• UroGen Pharma GAAP EPS of -$1.13 beats by $0.05, revenue of $16.1M misses by $4.05M
• UroGen gets FDA nod for extending duration of Jelmyto admixture
• UroGen Pharma GAAP EPS of -$1.18 beats by $0.12, revenue of $16.6M misses by $0.68M, reaffirms FY revenue guidance
• UroGen Pharma GAAP EPS of -$1.25 beats by $0.09, revenue of $13.56M misses by $1.62M
• UroGen wins Buy rating at Berenberg on potential in bladder cancer
• UroGen Pharma gets FDA nod to begin phase 1 trial of UGN-301 for bladder cancer
• UroGen Pharma GAAP EPS of -$1.27 misses by $0.07, revenue of $16.17M misses by $0.32M
• UroGen begins phase 3 trial of UGN-102 to treat bladder cancer
• UroGen pharma reports inducement grant to 13 new employees
• UroGen Pharma slips on Q3 earnings miss and disappointing guidance
• UroGen Pharma EPS misses by $0.06, misses on revenue
• UroGen bladder cancer candidate shows meaningful, durable response in mid-stage trial
• UroGen Pharma EPS in-line, beats on revenue